Best Oncology Companies in Central District, Israel
The 32 best Oncology companies in Central District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NeoTX.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Central District
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NeoTX Combinational tumor-targeting protein drugs for cancer | $101M | 80 mo ago | Series C | Asher Nathan CEO | 33 | — | — | — |
| 2 | Nucleix Developer non-invasive molecular cancer diagnostic tests | $88M | 58 mo ago | Series C | — | 62 | WordPressApple iCloud MailMicrosoft 365+24 | 163 patents DNA methylation profiling and liquid biopsy diagnostics for cancer detection | — |
| 3 | P-Cure Imaging-based proton radiation therapy for cancer treatment | $30M | 87 mo ago | Series B | Michael Marash Founder & CEO | 31 | WordPressMySQLPHP+13 | 70 patents Integration of proton therapy hardware and patient positioning/support systems for radiotherapy | — |
| 4 | Curesponse Provider of a tissue culture system to analyze cancer growth and drug response | $14M | 59 mo ago | Series B | Guy Neev Co-Founder & CEO | 16 | WordPressMySQLPHP+17 | — | — |
| 5 | Todos Medical Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | $7M | 61 mo ago | Public | — | 7 | — | 42 patents Infrared spectroscopic blood analysis for Alzheimer and cancer biomarker detection | — |
| 6 | JaxBio Developer of an AI-based chip for genetic and epigenetic profiling | $6M | 27 mo ago | Seed | Dror Feldheim Co-Founder | — | — | — | — |
| 7 | Trobix Bio Developer of microbiome-based therapeutics that address various therapeutic areas | $6M | 43 mo ago | Series A | — | 9 | — | — | — |
| 8 | MyBiotics Developer of microbiome-based therapeutics to treat various diseases | $5M | 53 mo ago | Seed | David Daboush Co-Founder & CEO | 27 | — | — | — |
| 9 | Efranat Cancer immunotherapies based on glycoprotein mimics | $4M | 143 mo ago | Series A | Uri Yogev CEO | 13 | — | 19 patents Immunotherapy compositions using macrophage activating factor for papilloma and cancer treatment | — |
| 10 | Predictive Therapeutics Developing tumor-cell coating molecules as therapy for cancer | $2M | 132 mo ago | Series A | Asher Nathan Co-Founder & CEO | — | — | — | — |
| 11 | Formulex Developer of cannabinoid drug products | $1M | 213 mo ago | Series A | Galia Krayz CEO | — | — | — | — |
| 12 | Limaca Medical Developing endoscopic ultrasound fine needle biopsy system | $1M | 71 mo ago | Seed | Assaf Klein CEO | 5 | — | 25 patents Biopsy and tissue sampling instruments for minimally invasive medical procedures | — |
| 13 | Biokine Therapeutics Developing CXCR4 antagonist drugs for cancer | $1M | 211 mo ago | Funding Raised | Amnon Peled Co-Founder & CEO | — | — | 263 patents CXCR4 antagonist peptide therapeutics for cancer treatment | — |
| 14 | Real Imaging Holdings Imaging solutions and cancer detection devices for the treatment of breast cancer | $930K | 158 mo ago | Seed | Ori Elan Co-Founder & Director | — | — | 150 patents Holographic display systems for medical imaging and augmented reality visual interfaces. | — |
| 15 | Semorex Research-based company developing therapeutics for treatment of cancer | $327K | 223 mo ago | Acqui-Hired | Maghsoud Dariani CEO & President | — | — | 10 patents Chemiluminescent therapies for proliferative diseases and polymer‑based fungal detection diagnostics | — |
Top 12 Oncology companies in Central District
#1
Seed · Netanya, Central District · founded 2020$6Mraised▾
Developer of an AI-based chip for genetic and epigenetic profiling. It offers a set of biomarkers that assists with the identification of different kinds of cancer. It has features for diagnostic tests with a multi-cancer approach system. The chip can be used for detecting genetic and epigenetic profiles
- Jul 2024Grant (prize money)$2.7M
- Jan 2023Grant (prize money)$9.1M
- Jan 2023Grant (prize money)$1.9M
- 2022Seed$6M
#2
Series C · Rehovot, Central District · founded 2008 · 62 employees$88.5Mraised▾
Developer non-invasive molecular cancer diagnostic tests. The company uses DNA methylation patterns (epigenetics) to detect cancer using proprietary biomarker assays. Its first product, the Bladder EpiCheck is used to diagnose bladder cancer. In addition, the company has developed diagnostic tests for colorectal cancer and lung cancer.
- Dec 2021Series C$22M
- Apr 2021Grant (prize money)$60.6K
- Apr 2021Series C$55M
- Nov 2018Grant (prize money)$2.8M
#3
Series A · Netanya, Central District · founded 2018 · 9 employees$6Mraised▾
Developer of microbiome-based therapeutics that address various therapeutic areas. The company is leveraging TBX technology that combines proprietary molecular engineering and computational algorithms tools to develop CRISPR-based synthetic phages for precision delivery of DNA payloads to target bacteria. It has developed a pipeline for oncology indications and gut inflammatory disorders.
- Mar 2023Series A$3M
- Jul 2020Series A$3M
#4
Series C · Rehovot, Central District · founded 2016 · 33 employees$100.9Mraised▾
NeoTX is focussed on developing immunotherapy-based late-stage cancer drugs. Its lead candidate Anyara (protein drug) is a TTS (Tumor Targeting Superantigen) which claims to increase the ability of the immune system to recognize the tumor. The candidate has finished clinical phase 1 trials for lung cancer, renal cell cancer and pancreatic cancer where it was studied as a single agent as well as in combination with docetaxel (chemotherapy). In October 2016, NeoTX entered into a partnership with Active Biotech for the development and commercialization of Anyra. As of December 2016, it is planning for a trial in combination with drugs that inhibit checkpoint dampening of the immune system.
- Feb 2020Series C$45M
- Oct 2019Series B$37.9M
- Aug 2019Series A$9.2M
- Oct 2016Series A$8.8M
#5
Seed · Rehovot, Central District · founded 2014 · 27 employees$4.7Mraised▾
Developer of microbiome-based therapeutics to treat various diseases. The company's product pipeline for cancer vaginal dysbiosis and the gastrointestinal solution is under the preclinical phase. It uses fermentation and formulation technology for the development of therapeutics. The company's technology platform includes MyCrobe (Single strain fermentation and formulation technology), SuperDonor (microbiome production and recovery technology), SuperDonor Select (Next-generation multi-strain technology), and MyLiveIn (AI-enabled design platform)
- May 2022Grant (prize money)$53.8K
- Feb 2021Seed—
- Oct 2020Grant (prize money)$2.4M
- Jun 2020Grant (prize money)$2.2M
#6
Public · Rehovot, Central District · founded 2009 · 7 employees$7.3Mraised▾
Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders. The first applications in the pipeline are for the diagnosis of breast cancer, colorectal cancer, lung cancer, Alzheimer's, and covid-19. The proprietary platform uses Total Body Infrared Analysis on small volumes of patient blood samples to obtain a 'biochemical fingerprint' of the immune system.
- Sep 2021Post IPO$2M
- Jan 2021Post IPO$3.4M
- Aug 2020Post IPO$275K
- 2020Post IPO$163K
#7
Series B · Rehovot, Central District · founded 2018 · 16 employees$14Mraised▾
Provider of a tissue culture system to analyze cancer growth and drug response. It preserves the cancer tissue (vasculature and immune system) to detect cancer growth in the body. It offers cResponse test that assesses individual patient’s tumor tissue via a biopsy or surgery, responds to a variety of cancer treatments. The test is combined with genomic analysis, for optimal adjustment of each cancer patient’s treatment.
#8
Series B · Lod, Central District · founded 2007 · 31 employees$30Mraised▾
P-Cure is the provider of image-guided solutions primarily for cancer treatment. It has developed a delivery system enabling the use of inexpensive fixed beam technologies for the treatment of cancer indications. Its first product called P-Artis is based on a diagnostic-quality computed tomography (CT) that enables the treatment planning, positioning and treatment delivery for cancer patients in a seated position. In September 2016, this upright imaging system has received FDA approval.
- Jul 2019Series B$15M
#9
Seed · Netanya, Central District · founded 2017 · 5 employees$1.2Mraised▾
Limaca Medical is an early stage company developing an endoscopic ultrasound fine needle biopsy system. As of Apr 2017, the product is in the technology development stage and the company is operating from Trendlines. It hasn't disclosed the product information and development details.
- Nov 2020Seed$1.2M
#10
Series A · Rehovot, Central District · founded 2009 · 13 employees$4.5Mraised▾
Efranat develops cancer immunotherapies based on glycoprotein mimics. It targets the Vitamin D binding protein that is known to activate macrophage activity and whose activity is suppressed in cancer patients. Its lead candidate mimics this glycoprotein and acts as an immunomodulator, triggering an immune response against tumor cells. It is currently in phase I trials for solid tumors.
- Nov 2014Series A$4.5M
- Nov 2011Seed—
#11
Series A · Rehovot, Central District · founded 2015$2.5Mraised▾
Predictive Therapeutics is a clinical stage oncology company focussed on developing immunotherapies. Its approach is based on acquiring undervalued late stage assets for the clinical development. It is currently building a late-stage pipeline of differentiated cancer therapies with the lead candidate PT-101, which coats tumor cells with molecules which direct the patient’s immune system against the tumor and claims to through the phase 3 clinical development with acceptable safety.
- Oct 2015Series A$2.5M
#12
Series A · Rehovot, Central District · founded 2001$1.4Mraised▾
Formulex is a developer of cannabinoid drug products. The company is a developer of nano-technology based drug delivery and formulations. The products developed are Solumer, OMEXA and NASAX.
- Feb 2009Series A$1.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Israel
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 263 Israel-affiliated papers.
- Tel Aviv University55
- Weizmann Institute of Science42
- Technion – Israel Institute of Technology42
- Hadassah Medical Center33
- Hebrew University of Jerusalem31
- Immune system2→40
- Tumor microenvironment5→42
- Cancer research6→30
- Immunotherapy1→24
- Cancer immunotherapy1→23
- Tumor microenvironment6→51
- Immune system3→37
- Cancer research2→30
- Immunotherapy2→30
- Melanoma2→8
- Tumor microenvironment1→11
- Immune system1→9
- Immunology1→4
- Cancer research1→4
Where oncology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.